Adiutrix Therapeutics
Publicly observedNew York, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | New York | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Adiutrix Therapeutics | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | SECASJ6KJBY5 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant17 Sept 2024Publicly observed
NIH SBIR/STTR award: Platform technology to identify and develop first-in-class anti-fibrotic therapeutics through inhibition of collagen CP4H
USD 1,102,737.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
- Grant17 Sept 2024Publicly observed
NIH SBIR/STTR award: Platform technology to identify and develop first-in-class anti-fibrotic therapeutics through inhibition of collagen CP4H
USD 1,027,583.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.